TECH - Turning Sugars Into Pure Pharma-Grade Rare Cannabinoids:This Company's Breakthrough | Benzinga
In an exclusive interview with Benzinga, Dr. Shane Johnson, MD, senior vice president and general manager of BayMedica, sheds light on the company's innovative approach to cannabinoid production.
With a background in cannabis and cannabinoid science, and credentials from Stanford University School of Medicine, Dr. Johnson is at the forefront of this scientific revolution.
How does BayMedica's biosynthesis platform revolutionize cannabinoid production? And, what are the key benefits for the cannabinoid industry?
"Previously, the cannabinoid market focused mainly on THC and CBD, but now we recognize the existence of around 150 cannabinoids, many with unique properties. This has led to increased sales of rare cannabinoids like CBN, CBG, CBC, THCV, etc,” Johnson said. "These can be extracted from hemp or produced through chemistry and precision fermentation. For rarer cannabinoids, modern manufacturing techniques are more effective than plant-based methods, ensuring the end product matches the compound found in the plant."
The Biosynthesis Revolution
BayMedica's pioneering biosynthesis platform is revolutionizing the production of rare cannabinoids. This innovative process turns simple sugars into pure, pharmaceutical-grade cannabinoids, bypassing the need for traditional plant cultivation or extraction.
The method employs common brewer's yeast, transforming it into ...